ReviewAJOG global reports2025
Prevalence of newly diagnosed essential hypertension within one year postpartum: a systematic review and meta-analysis.
Review in AJOG global reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association Between Gestational Blood Pressure Trajectories and Postpartum Normotension Recovery in Hypertensive Disorders: Retrospective Cohort Study.JMIR public health and surveillance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Pregnancy induces a state of cardiovascular stress and can lead to long-lasting effects irrespective of complications in pregnancy. However, the magnitude of these effects needs to be clarified. This study seeks to determine the prevalence of newly diagnosed essential hypertension within one year postpartum among the obstetric population who experienced uncomplicated pregnancies. Data sources: A comprehensive search of the databases MEDLINE, Cochrane Central Register of Controlled Clinical Trials, EMBASE, Web of Science, and CINAHL was conducted for studies published up to March 2023. Study eligibility criteria: Studies that assessed healthy individuals between 12 weeks and one year postpartum with newly diagnosed essential hypertension (≥140/90) and without pregnancy complications were included. Case studies, systematic reviews, and meta-analyses were excluded, along with studies involving pregnant patients who were either less than three months or more than one year postpartum, those with pre-existing hypertension or pregnancy complications, or those with pre-existing medical conditions. Study appraisal and synthesis methods: Meta-analyses using random-effects models calculated pooled prevalence estimates and examined mean arterial pressure, systolic blood pressure, and diastolic blood pressure. Subgroup analyses considered the timing of blood pressure assessment, geographical location, and the presence of interventions. Results: In eight studies with 3070 participants, the prevalence of newly diagnosed hypertension was 2.96% (95% confidence interval [CI], 1.15%-7.43%; I², 80%). No significant differences were observed in the subgroup analyses. Across 30 studies with 1782 individuals, the average systolic blood pressure was 109.88 mmHg (95% CI, 108-111.75; I², 92.2%), and diastolic blood pressure was 70.99 mmHg (95% CI, 68.84-73.14; I², 95.7%). In 12 studies with 339 individuals, the average mean arterial pressure was 82.01 mmHg (95% CI, 79.84-84.19; I², 93.6%). Conclusions: These findings suggest that nearly 3 in 100 healthy individuals with uncomplicated pregnancies are diagnosed with de novo essential hypertension within one year postpartum. This underscores the need to extend cardiovascular screening to all postpartum individuals for one year, regardless of medical or pregnancy history.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.